Important NoticeThis app is for educational purposes only. You must be 18+ to use it. We do not sell any peptides on this site.

Peptide Library / Detail
Half-life
Not extensively characterized; short peptides typically have half-lives of minutes to hours
Delivery
Oral administration or subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Vesugen is a short tripeptide (Lys-Glu-Asp / KED) derived from vascular tissues that acts as a bioregulatory peptide with geroprotective and vascular protective properties. Originally identified in research on endogenous growth regulation, it has been extensively studied for its effects on cellular aging, vascular health, and tissue regeneration. Vesugen functions as a epigenetic regulator that modulates gene expression in aging cells without altering DNA sequences.
Research protocols typically involve oral administration or subcutaneous injection of 0.1-1.0 mg per day for cycles of 10-20 days, repeated periodically (every 3-6 months). Studies have examined both continuous and intermittent dosing regimens. Clinical observations in elderly patients with polymorbidity used 20-day courses. Vesugen is often studied as part of peptide bioregulator combinations rather than as monotherapy.
Vesugen (KED) acts as an epigenetic regulator by modulating chromatin structure and gene expression patterns in aging cells. It influences the transcriptional activity of genes involved in cellular senescence, vascular endothelial function, and extracellular matrix synthesis. Research demonstrates it upregulates genes associated with cell proliferation and tissue repair while downregulating senescence markers. In mesenchymal stem cells and fibroblasts, Vesugen normalizes age-related changes in gene expression profiles. Studies indicate it provides vasoprotective effects during atherosclerosis and restenosis by modulating vascular cell function and reducing pathological remodeling.
Vesugen is a short tripeptide (Lys-Glu-Asp / KED) derived from vascular tissues that acts as a bioregulatory peptide with geroprotective and vascular protective properties. Originally identified in research on endogenous growth regulation, it has been extensively studied for its effects on cellular aging, vascular health, and tissue regeneration. Vesugen functions as a epigenetic regulator that modulates gene expression in aging cells without altering DNA sequences.
Vesugen has an approximate half-life of Not extensively characterized; short peptides typically have half-lives of minutes to hours. The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.
Vesugen is typically delivered via oral administration or subcutaneous injection. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.
Vesugen (KED) acts as an epigenetic regulator by modulating chromatin structure and gene expression patterns in aging cells. It influences the transcriptional activity of genes involved in cellular senescence, vascular endothelial function, and extracellular matrix synthesis. Research demonstrates it upregulates genes associated with cell proliferation and tissue repair while downregulating senescence markers. In mesenchymal stem cells and fibroblasts, Vesugen normalizes age-related changes in gene expression profiles. Studies indicate it provides vasoprotective effects during atherosclerosis and restenosis by modulating vascular cell function and reducing pathological remodeling.
Studied benefits of Vesugen include: Protects cells from age-related deterioration and senescence, Promotes vascular health and may reduce atherosclerosis progression, Modulates gene expression in aging fibroblasts and stem cells, Supports neuronal differentiation and neurogenesis in aging models, May improve work ability and functional capacity in elderly populations, Demonstrates geroprotective effects in patients with chronic polymorbidity, Enhances cellular repair mechanisms in vascular and connective tissues, Normalizes expression of genes involved in extracellular matrix regulation. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.
Reported side effects of Vesugen include: Minimal adverse effects reported in published clinical studies, Generally well-tolerated in elderly populations with polymorbidity, Specific adverse event profiles not extensively characterized in literature, Long-term safety data beyond study durations limited, Individual sensitivity to peptide formulations may vary. Always discuss potential side effects with a licensed healthcare provider before using any research peptide.
Other recovery compounds in the Peptides Calculator library.
Half-life · Approximately 1-2 hours (estimated based on similar short peptides)
Half-life · Approximately 30-60 minutes (varies by delivery method and formulation)
Half-life · Estimated 1-3 hours (typical for short tripeptides)
Half-life · 30-60 minutes
Half-life · Approximately 2-3 hours
Half-life · Unknown - insufficient pharmacokinetic data